Remove Article Remove Epilepsy Remove Pharmaceutical
article thumbnail

GW suffers major blow as US sinks bid to patent cannabinoids for epilepsy

Cannabis Law Report

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

article thumbnail

Cannabis Patents are Approaching the Patent Trial and Appeal Board

Canna Law Blog

9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CBD Market Report

Project CBD

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC7400098/.

CBD 144
article thumbnail

Press Release: Cabot Wealth Management Upped Gw Pharmaceuticals Plc (GWPH) Stake by $914,524; Share Price Declined; Unitedhealth Group (UNH) Holder New England Investment & Retirement Group Has Raised Stake

Cannabis Law Report

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. based on its latest 2019Q2 regulatory filing with the SEC.

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

article thumbnail

Global Legal Chronicle Article: Medical Cannabis regulation slowly advances in Brazil

Cannabis Law Report

In Brazil, the initial step to allow the use of cannabis sativa for medical purposes was taken in 2014, when the Judiciary granted the first injunction to authorize a patient to import and use cannabidiol-rich oil (CBD) for the refractory epilepsy treatment. 399/15 intends to amend article 2 of Law No.

Sativa 59
article thumbnail

GW Pharmaceuticals Wins the Queens Prize for Innovation

SpeedWeed

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” .